Drug discovery and optimization based on the co-crystal structure of natural product with target

被引:7
|
作者
Chen, Xing [1 ,3 ]
Varghese, Swapna [2 ]
Zhang, Zhaoyan [1 ]
Du, Juncheng [1 ]
Ruan, Banfeng [4 ]
Baell, Jonathan B. [2 ]
Liu, Xinhua [1 ]
机构
[1] Anhui Med Univ, Sch Pharm, Inflammat & Immune Mediated Dis Lab Anhui Prov, Hefei 230032, Peoples R China
[2] Monash Univ, Monash Inst Pharmaceut Sci, Med Chem, Melbourne, Vic 3052, Australia
[3] Anhui Med Univ, Sch Publ Hlth, Key Lab Populat Hlth Life Cycle, Hefei 230032, Peoples R China
[4] Hefei Univ, Key Lab Biofabricat Anhui Higher Educ, Hefei 230601, Peoples R China
基金
中国博士后科学基金;
关键词
BISTRAMIDE-A; CELL-CYCLE; PROTEIN PHOSPHATASE-1; RAPAMYCIN AY-22,989; IN-VITRO; INHIBITION; COMPLEX; PACTAMYCIN; POTENT; GELDANAMYCIN;
D O I
10.1016/j.ejmech.2024.116126
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Due to their structural diversities and prevalent biological activities, natural products (NPs) are momentous resources for drug discovery. Although NPs have a wide range of biological activities, many exhibit structural complexity that leads to synthetic difficulties, which combines with inefficient biological activity, toxicity, and unfavorable pharmacokinetic characteristics and ultimately imparts poor safety and efficacy outcomes. Progress in crystallization and computational techniques allow crystallography to have a seasonable influences on drug discovery. By co -crystallizing with proteins, therapeutic targets of NPs in specific diseases can be identified. By analyzing the co -crystal information, the structure -activity relationships (SARs) of NPs targeting specific proteins can be grasped. Under the guidance of co -crystal information, directional structural modification and simplification are powerful strategies for overcoming limitations of NPs, improving the success rate of NP -based drug discovery, and obtaining NP -based drugs with high selectivity, low toxicity and favorable pharmacokinetic characteristics. Here, we review the cocrystal information of a selection of NPs, focusing on the SARs of NPs reflected by co -crystal information and the modification and simplification strategies of NPs, and discuss how to apply co -crystal information in the optimization of NP -based lead compound.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Guiding principles for natural product drug discovery
    Camp, David
    Davis, Rohan A.
    Evans-Illidge, Elizabeth A.
    Quinn, Ronald J.
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (09) : 1067 - 1084
  • [42] Bioassay development in natural product drug discovery
    Vuorela, P.
    PLANTA MEDICA, 2006, 72 (11) : 962 - 962
  • [43] Metabolomics at the Service of Natural Product Drug Discovery
    Roullier, Catherine
    MARINE DRUGS, 2020, 18 (01)
  • [44] Crystal structure of the co-crystal butylparaben-isonicotinamide (1/1)
    Bhardwaj, Rajni M.
    Yang, Huaiyu
    Florence, Alastair J.
    ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2016, 72 : 53 - +
  • [45] A Rationale for Drug Design Provided by Co-Crystal Structure of IC261 in Complex with Tubulin
    Xian, Jinghong
    Bu, Faqian
    Wang, Yuxi
    Long, Fangyi
    Zhang, Zhixiong
    Wu, Chengyong
    Tao, Yiran
    Wang, Ting
    Wang, Guan
    MOLECULES, 2021, 26 (04):
  • [46] One class classification as a practical approach for accelerating π-π co-crystal discovery
    Vriza, Aikaterini
    Canaj, Angelos B.
    Vismara, Rebecca
    Cook, Laurence J. Kershaw
    Manning, Troy D.
    Gaultois, Michael W.
    Wood, Peter A.
    Kurlin, Vitaliy
    Berry, Neil
    Dyer, Matthew S.
    Rosseinsky, Matthew J.
    CHEMICAL SCIENCE, 2021, 12 (05) : 1702 - 1719
  • [47] Co-crystal forms of the BCS class IV drug sulfamethoxazole
    Alsubaie, Moneerh
    Aljohani, Marwah
    Erxleben, Andrea
    McArdle, Patrick
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : E192 - E192
  • [48] Crystal structure of a 2:1 co-crystal of meloxicam with acetylendicarboxylic acid
    Tantardini, Christian
    Arkhipov, Sergey G.
    Cherkashina, Ksenya A.
    Kil'met'ev, Alexander S.
    Boldyreva, Elena V.
    ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2016, 72 : 1856 - +
  • [49] Natural product drug discovery: the successful optimization of ISP-1 and halichondrin B
    Yeung, Bryan K. S.
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2011, 15 (04) : 523 - 528
  • [50] Polymorphism of co-crystals: Co-crystal polymorphs of an analgesic drug, ethenzamide
    Aitipamula, Srinivasulu
    Chow, Pui Shan
    Tan, Reginald B. H.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2008, 64 : C476 - C477